Fazle Akbar, S.M.
(aThird Department of Internal Medicine, Ehime University School of Medicine, Ehime,, , Japan)
,
Kajino, K.
,
Tanimoto, K.
,
Kurose, K.
,
Masumoto, T.
,
Michitaka, K.
,
Horiike, N.
,
Onji, M.
Background/Aims: Treatment of hepatitis B virus carriers by vaccine containing hepatitis B surface antigen with Pre-S protein and HBsAg/ anti-HBs complex has been reported and these studies have constituted a new and promising concept for the treatment of HBV-carriers. The present communication, a p...
Background/Aims: Treatment of hepatitis B virus carriers by vaccine containing hepatitis B surface antigen with Pre-S protein and HBsAg/ anti-HBs complex has been reported and these studies have constituted a new and promising concept for the treatment of HBV-carriers. The present communication, a placebo-controlled trial of vaccination in HBV-transgenic mice, was designed to examine the impact of vaccination using a high dose of HBsAg for a duration of 12 months to achieve further insights about the dose, duration and effectiveness of vaccine therapy. Another aim of this study was to analyse the mechanism underlying the antiviral and immunomodulatory potentiality of vaccine therapy in HBV-transgenic mice.Methods: HBV-transgenic mice positive for HBV DNA, hepatitis B surface antigen and hepatitis B e antigen in sera received either HBV-vaccine containing HBsAg in complete Freunds' adjuvant (CFA), intraperitoneally, once a month for 12 consecutive months (vaccine recipients), or only CFA, intraperitoneally once in a month for 12 consecutive months (placebo recipients). Thirty-two vaccine-recipient and 16 placebo-recipient HBV-transgenic mice were injected, checked and followed on a monthly basis for the entire duration of 12 months.Results: Of the 32 transgenic mice from the vaccine-recipient group, 25 became completely negative for HBsAg and 30 for HBeAg. Five mice developed anti-HBs in sera after the observation period of 12 months. Semiquantitative estimation of HBV DNA by polymerase chain reaction showed that vaccination resulted in a decrease of HBV DNA in sera. Placebo-recipient transgenic mice did not show any significant change in the titres of HBV markers after receiving 12 monthly injections of CFA. Interleukin-2 could be detected in sera from vaccine-recipient transgenic mice, but not in placebo-recipient transgenic mice.Conclusions: Vaccination with a high dose of HBsAg in adjuvant over a long period had a significant antiviral as well as immunomodulatory potential in HBV-transgenic mice. This inspires optimism that vaccine alone or in combination with antiviral agents can be used successfully for the treatment of human HBV-carriers.
Background/Aims: Treatment of hepatitis B virus carriers by vaccine containing hepatitis B surface antigen with Pre-S protein and HBsAg/ anti-HBs complex has been reported and these studies have constituted a new and promising concept for the treatment of HBV-carriers. The present communication, a placebo-controlled trial of vaccination in HBV-transgenic mice, was designed to examine the impact of vaccination using a high dose of HBsAg for a duration of 12 months to achieve further insights about the dose, duration and effectiveness of vaccine therapy. Another aim of this study was to analyse the mechanism underlying the antiviral and immunomodulatory potentiality of vaccine therapy in HBV-transgenic mice.Methods: HBV-transgenic mice positive for HBV DNA, hepatitis B surface antigen and hepatitis B e antigen in sera received either HBV-vaccine containing HBsAg in complete Freunds' adjuvant (CFA), intraperitoneally, once a month for 12 consecutive months (vaccine recipients), or only CFA, intraperitoneally once in a month for 12 consecutive months (placebo recipients). Thirty-two vaccine-recipient and 16 placebo-recipient HBV-transgenic mice were injected, checked and followed on a monthly basis for the entire duration of 12 months.Results: Of the 32 transgenic mice from the vaccine-recipient group, 25 became completely negative for HBsAg and 30 for HBeAg. Five mice developed anti-HBs in sera after the observation period of 12 months. Semiquantitative estimation of HBV DNA by polymerase chain reaction showed that vaccination resulted in a decrease of HBV DNA in sera. Placebo-recipient transgenic mice did not show any significant change in the titres of HBV markers after receiving 12 monthly injections of CFA. Interleukin-2 could be detected in sera from vaccine-recipient transgenic mice, but not in placebo-recipient transgenic mice.Conclusions: Vaccination with a high dose of HBsAg in adjuvant over a long period had a significant antiviral as well as immunomodulatory potential in HBV-transgenic mice. This inspires optimism that vaccine alone or in combination with antiviral agents can be used successfully for the treatment of human HBV-carriers.
참고문헌 (20)
Dusheiko 571 1991 Hepatitis B
Hepatology Hoofnagle 7 758 1987 10.1002/hep.1840070424 Chronic type B hepatitis and “healthy” HBsAg asymptomatic carrier state
Hepatology Thomas 2 116S 1982 Immunological mechanism in chronic hepatitis B virus infection
Thomas 612 1991 Pathogenesis of chronic HBV infection and mechanisms of action of anti viral compounds
Perillo 616 1991 Treatment of chronic hepatitis B
Gastroenterology Hoofnagle 95 1318 1988 10.1016/0016-5085(88)90367-8 Randomized controlled trial of recombinant human γ-interferon in patients with chronic hepatitis B
J Clin Invest Vitiello 95 341 1995 10.1172/JCI117662 Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. 1. Induction of a primary cytotoxic T lymphocyte response in humans
Immunology Akbar 78 468 1993 Low responsiveness of hepatitis B virus transgenic mice in antibody response to T-cell-dependent antigen: defect in antigen-presenting activity of dendritic cells
Immunology Akbar 87 519 1996 10.1046/j.1365-2567.1996.516576.x Up regulation of MHC class II antigen on dendritic cells from hepatitis B virus transgenic mice: abrogation of immune response defect to a T-cel-dependent antigen
J Immunol Millich 130 1401 1983 10.4049/jimmunol.130.3.1401 Genetic regulation of the immune response to hepatitis B virus surface antigen (HBsAg). III. Circumvention of non responsiveness in mice bearing HBsAg non responder haplotypes
J Virol Guilhot 67 7444 1993 10.1128/JVI.67.12.7444-7449.1993 Interleukin-2 down regulates hepatitis B virus gene expression in transgenic mice by a post transcriptional mechanism
Hepatology Chisari 22 1316 1995 Hepatitis B virus transgenic mice: insights into the virus and disease
J Med Virol Mancini 39 67 1993 10.1002/jmv.1890390113 Induction of anti-hepatitis B surface antigen (HBsAg) antibodies in HBsAg producing transgenic mice: a possible way of circumvent “non response” to HBsAg
J Immunol Wirth 154 2504 1995 10.4049/jimmunol.154.5.2504 Breaking tolerance leads to autoantibody production but not autoimmune liver disease in hepatitis B virus envelope transgenic mice
AI-Helper
※ AI-Helper는 부적절한 답변을 할 수 있습니다.